One patient, one custom drug: a bold experiment for a rare syndrome

NCT ID NCT07197268

Ongoing Disease control Sponsor: n-Lorem Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a custom-made drug called an antisense oligonucleotide (ASO) designed specifically for one person with Bainbridge-Ropers syndrome, a rare genetic condition that causes developmental delays. The drug aims to correct the effects of a specific ASXL3 gene mutation. The main goals are to check if the drug is safe and to see if it improves motor skills over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized antisense oligonucleotide (nL-ASXL3-001)
What this could lead to: If it works, this could point toward a treatment for Bainbridge-Ropers syndrome caused by ASXL3 mutations.
What could go wrong: This is an extremely early, single-patient study. It may not work for others, and safety is still unknown. There is no guarantee of benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates